News Snapshot:
COVAXX has started dosing healthy adult participants in a Phase I clinical trial of its Covid-19 vaccine candidate, UB-612, in Taiwan. Each participant will receive two doses of UB-612 Covid-19 vaccine candidate. Credit: Dimitri Houtteman from Pixabay. Share Article COVAXX has started dosing healthy adult participants in a Phase I clinical trial of its Covid-19 vaccine candidate, UB-612, in Taiwan. The dose-escalation study received funds worth approximately $15m (NT$ 430m) from the Ministry of Health and Welfare in Taiwan. UB-612 is a multitope peptide-based vaccine candidate that is meant to activate the B and T-cell arms of the immune system....
